This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DURECT Corporation Q1 2010 Earnings Call Transcript

DURECT Corporation (DRRX)

Q1 2010 Earnings Call Transcript

May 10, 2010 4:30 pm ET


Matt Hogan – CFO

Jim Brown – President and CEO

Joe Stauffer – Chief Medical Officer


David Amsellem – Piper Jaffray

Andrew Hilgenbrink – Jefferies & Co.

Jim Molloy – Caris & Co.

Jeffrey DeSeibert – KB Advisors



Thanks so much for holding, everyone. Welcome to the DURECT first quarter earnings conference call. Just as a reminder, today's call is being recorded. Now at this time, I will turn things over to our host, Mr. Matt Hogan. Matt, please go ahead.

Matt Hogan

Okay, thank you. Good afternoon. Welcome to our first quarter 2010 earnings conference call. This is Matt Hogan, CFO at DURECT. This call will begin with a brief review of our financial results, and then, Jim Brown, our President and CEO will provide an update on our business. We will then open up the call for a Q&A session.

Before beginning, I would like to remind you of our Safe Harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks are including in our SEC filings, including our 10-K and our 10-Qs under the heading Risk Factors.

Let me now turn to our financials. Total revenue was $7.7 million in the first quarter of 2010, which compares to $6.2 million in the first quarter of 2009. Revenue from our R&D collaborations was $3.8 million in the first quarter this year, as compared to $3.7 million in the first quarter last year. Revenue from this source always fluctuates from quarter-to-quarter, depending on the state of development under the various programs, and our role in those programs.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DRRX $1.03 0.00%
AAPL $95.01 0.00%
FB $99.75 0.00%
GOOG $682.74 0.00%
TSLA $147.99 0.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs